ArticleClinical immunology (Orlando, Fla.)2009

Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.

Mark J Dobrzanski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.